What is BMY stock price today?

BMY (Bristol Myers Squibb Co) stock is trading at $62.37 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is BMY stock going up or down today?

BMY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy BMY stock now?

The decision to buy BMY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is BMY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for BMY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is BMY stock overvalued or undervalued?

BMY currently trades at a P/E ratio of 18.03 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if BMY is fairly priced.

What is BMY's P/E ratio?

BMY has a price-to-earnings (P/E) ratio of 18.03, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is BMY's market cap?

BMY (Bristol Myers Squibb Co) has a market capitalization of $127.01 billion, making it a mid-cap stock.

What is BMY's price to book ratio?

BMY trades at a price-to-book (P/B) ratio of 6.74, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does BMY pay dividends?

Yes, BMY pays dividends with a current yield of 0.04%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is BMY's dividend yield?

BMY's dividend yield is 0.04%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is BMY stock a good long-term investment?

BMY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is BMY's revenue growth rate?

BMY has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, BMY is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in BMY?

Key risks for BMY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does BMY compare to its competitors?

Compare BMY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize BMY's performance and positioning.

What is BMY's stock price target for 2026?

Our AI model provides price targets for BMY based on fundamental analysis: Bull case $81.08 (+30%), Base case $71.73 (+15%), Bear case $56.13 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about BMY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for BMY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is BMY's next earnings report?

BMY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

BMY - Bristol Myers Squibb Co

NYSE * Health Care * Pharmaceuticals

$62.37

+$1.27 (+2.08%)

About Bristol Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

BMY Key Statistics

Market Cap

$127.01B

P/E Ratio

18.03

P/B Ratio

6.74

EPS

$3.46

Dividend Yield

0.04%

Revenue Growth

+0.0%

Profit Margin

0.1%

Employees

32,500

How BMY Compares to Peers

BMY has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

BMY has the highest profit margins in Pharmaceuticals

BMY is the smallest among peers, which may offer higher growth potential

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
BMY(This stock)	$127.01B	18.0	0%	0.1%	-
AMZNAmazon Com	$2.25T	29.3	0%	0.1%	vs AMZN

Bristol Myers Squibb Co Company Information

Headquarters: New York; U.S.A
Website: www.bms.com
Sector: Health Care
Industry: Pharmaceuticals

BMY - Bristol Myers Squibb Co

About Bristol Myers Squibb Co

BMY Key Statistics

How BMY Compares to Peers

Bristol Myers Squibb Co Company Information

BMY Lician Score

BMY Financial Snowflake

Upcoming Events for BMY